Kong Garheng
SEC-identified person · CIK 1435183 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Xeris Biopharma Holdings, Inc. XERS | Director | filed 2021 - 2026 |
| Laboratory Corp of America Holdings LH | Director | filed 2013 - 2026 |
| Digital Transformation Opportunities Corp. DTOC | Officer | filed 2023 - 2023 |
| Venus Concept Inc. VERO | Director | filed 2019 - 2023 |
| Alimera Sciences INC ALM | Director | filed 2012 - 2023 |
| Strongbridge Biopharma plc SBBP | Director | filed 2018 - 2021 |
| Castle Biosciences INC CSTL | Officer | filed 2019 - 2020 |
| Avedro INC AVDR | Director | filed 2019 - 2019 |
| Ocugen, Inc. OCGN | Director | filed 2014 - 2018 |
| Melinta Therapeutics, INC. /NEW/ MLNT | Director | filed 2012 - 2018 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.